Trial Profile
A phase ll study to show the feasibility of six months continuous administration of Docetaxel+TS-1 for patients with Stage lllA/lllB gastric cancer after surgical resection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Adverse reactions
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.
- 28 May 2013 Planned end date changed from 1 Dec 2012 to 31 Dec 2017 as reported by University Hospital Medical Information Network - Japan.
- 26 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.